No topic has taken over health podcasting like GLP-1 medications. Ozempic, Wegovy, Mounjaro and Zepbound have gone from diabetes-clinic vocabulary to dinner-table conversation in about three years, and roughly one in five American adults has now tried one. Every major health show has weighed in — some breathlessly, some skeptically, and a few with genuine scientific depth. Here's a map of who's saying what, and which episodes are worth your time.
Why this became podcasting's biggest health story
The trial numbers explain the noise. In the STEP trials, semaglutide (Wegovy) produced average weight loss around 15% of body weight; in the SURMOUNT trials, tirzepatide (Zepbound) pushed past 20% — territory previously reserved for bariatric surgery. Then the SELECT trial showed semaglutide cutting major cardiovascular events by about 20% in people with obesity and heart disease, which moved the story from cosmetic to cardiological. Add a telehealth industry built to prescribe at scale, a compounding-pharmacy gray market, supply shortages, and celebrities visibly shrinking while denying everything — and you have a story that is simultaneously pharmacology, economics and culture. That's long-form audio territory, and podcasts have covered it better than any other medium.
The science-first shows
Huberman Lab. Andrew Huberman, the Stanford neuroscientist whose show is among the biggest in the world, has approached GLP-1s through mechanism. His episode with Dr. Zachary Knight — the UCSF physiologist who studies the hunger neurons these drugs act on — is probably the single best explanation in audio of why GLP-1 agonists quiet appetite: slowed gastric emptying, signaling in the hypothalamus and brainstem, and the famous "food noise" reduction patients describe. The recurring Huberman theme: these drugs work, but rapid weight loss takes muscle with it unless resistance training and high protein intake are part of the plan.
The Peter Attia Drive. Attia — a Stanford- and Hopkins-trained physician focused on longevity medicine, and author of the #1 bestseller Outlive — has produced the deepest coverage anywhere, including multiple AMAs dedicated specifically to GLP-1s and interviews with obesity and metabolism researchers. His framing is consistently the adult in the room: these are genuinely important drugs; the lean-mass loss problem is real (a meaningful fraction of weight lost can be muscle); the discontinuation problem is unsolved — most people regain substantial weight after stopping, which makes these long-term therapies, not twelve-week fixes; and the off-label optimization crowd is way ahead of the data.
ZOE Science & Nutrition. The UK-based show fronted by Jonathan Wolf with epidemiologist Tim Spector brings the food-science angle: what happens to nutrition when people eat 30–40% fewer calories, why protein and micronutrient density suddenly matter far more, and how the food industry is scrambling to respond. Their GLP-1 episodes are the most practical listening for someone actually on the medication.
The skeptics
Maintenance Phase. Aubrey Gordon — author of What We Don't Talk About When We Talk About Fat — and journalist Michael Hobbes built an entire show on debunking diet culture, and their Ozempic episode (one of their most-shared ever) is the strongest counterargument in audio: questioning the framing of obesity as a disease to be medicated, the pharmaceutical marketing machine, the two-tier access problem where cash-pay telehealth serves the wealthy while insurance denies everyone else, and what mass appetite suppression does to a culture's relationship with food. Whatever your position, it's the sharpest critique available, and listening to it alongside Attia is the fastest way to understand the full debate.
The Doctor's Farmacy. Dr. Mark Hyman, the functional-medicine physician and longtime food-as-medicine advocate, is skeptical not of efficacy but of priorities: a system that medicates the downstream consequences of an ultra-processed food supply rather than fixing the food. His GLP-1 conversations consistently land on the same question — what happens to a society that treats its food environment as unfixable?
The culture beat. Journalist Johann Hari's book Magic Pill — built on his own year using Ozempic — sent him across the podcast circuit, including a widely shared Diary of a CEO appearance, articulating both the case for the drugs and twelve risks he couldn't dismiss. The New York Times' The Daily has run multiple episodes tracking the social story, from Hollywood to insurance fights.
What the shows agree on
Listen across the spectrum and a surprising consensus emerges. Muscle loss is the real physiological risk — clinician guests across Huberman, Attia and ZOE repeat that without resistance training and substantially increased protein, a quarter or more of lost weight can be lean mass, which is why an entire protein-products industry has pivoted to GLP-1 users. The drugs change behavior, not just appetite — the "quieting of food noise" comes up in nearly every patient account, and it's driving trials in alcohol use and other addictions, early results of which are genuinely promising. Coming off is the hard part — weight regain after discontinuation is the most consistent finding in the literature, and honest episodes treat these as chronic-disease medications. And access is the next battleground: compounded versions, telehealth prescribing standards, and insurance coverage are where the story moves in 2026, with oral semaglutide and next-generation multi-agonists already in the pipeline.
Where to start listening
For the science: Huberman's Zachary Knight episode, then Attia's GLP-1 AMAs. For the critique: Maintenance Phase's Ozempic episode. For practical guidance on the medication: ZOE's GLP-1 and protein episodes. For the cultural whole: Hari's long-form interviews. The conversation is moving quickly — the 2026 episodes already sound different from the 2024 ones — and the Health & Fitness and Nutrition charts are where new shows covering this space surface first.
Chart positions referenced are based on Reason.fm's daily-updated Health & Fitness and Nutrition category rankings.